Prediction of response: odds ratios (OR) and 95% confidence intervals (CI) of BASDAI 50 response; results are shown for univariate (total population and for each drug separately) and multivariate (total population only) logistic regression analysis
| Univariate analysis OR (95%CI) | Multivariate analysis (best model) OR (95%CI) | ||||||
|---|---|---|---|---|---|---|---|
| Total population (n = 99) | p Value | Infliximab (n = 69) | p Value | Etanercept (n = 30) | p Value | Total group (n = 99) | |
| *OR refers to the risk of achieving a BASDAI 50 response per year of disease duration/age; †OR refers to the risk per one grade on a 0–10 scale; ‡OR refers to the risk if HLA-B27 is positive (v negative); §OR refers to the risk per 1 mg/l increase of CRP; ¶OR refers to the risk if peripheral arthritis or enthesitis, respectively, is present (v absent). | |||||||
| Disease duration* | 0.93 (0.88 to 0.98) | 0.003 | 0.95 (0.89 to 1.00) | 0.050 | 0.89 (0.80 to 0.99) | 0.015 | 0.94 (0.89 to 0.99) |
| Age* | 0.94 (0.90 to 0.99) | 0.009 | 0.94 (0.88 to 0.995) | 0.026 | 0.95 (0.87 to 1.04) | 0.24 | |
| BASFI† | 0.75 (0.60 to 0.93) | 0.007 | 0.81 (0.63 to 1.04) | 0.088 | 0.47 (0.25 to 0.88) | 0.004 | 0.54 (0.38 to 0.76) |
| HLA-B27 positive‡ | 3.22 (0.78 to 13.3) | 0.092 | 2.94 (0.53 to 16.4) | 0.19 | 4.0 (0.32 to 50.2) | 0.27 | |
| CRP (mg/l)§ | 1.02 (1.001 to 1.04) | 0.035 | 1.02 (1.00 to 1.04) | 0.066 | 1.04 (0.99 to 1.09) | 0.12 | 1.02 (1.002 to 1.05) |
| BASDAI† | 1.34 (0.96 to 1.87) | 0.082 | 1.44 (0.97 to 2.12) | 0.061 | 1.03 (0.52 to 2.03) | 0.93 | 2.26 (1.34 to 3.81) |
| BASMI† | 0.88 (0.72 to 1.07) | 0.20 | 0.88 (0.69 to 1.11) | 0.26 | 0.85 (0.56 to 1.29) | 0.44 | |
| Peripheral arthritis¶ | 0.45 (0.20 to 1.02) | 0.053 | 0.53 (0.20 to 1.41) | 0.20 | 0.30 (0.06 to 1.42) | 0.12 | |
| Enthesitis¶ | 1.02 (0.46 to 2.27) | 0.96 | 1.07 (0.42 to 2.77) | 0.88 | 1.02 (0.22 to 4.78) | 0.98 | |